SCHEMBL6030409

SCHEMBL6030409

ClCCCn1cc(-c2ccccc2)cn1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.62
CREBBP Q92793 5/20 0.44
KDR P35968 1/20 0.42
EPHB4 P54760 1/20 0.42
KCNH2 Q12809 4/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
SOAT1 P35610 1/20 0.40
FEN1 P39748 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
GRIN2B Q13224 1/20 0.38
PDK2 Q15119 1/20 0.38
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11825597 0.83 L3MBTL1 (0.57) L3MBTL1CREBBPPDK2NAMPT
SCHEMBL2641177 0.83 L3MBTL1 (0.57) L3MBTL1CREBBPKDREPHB4KCNH2
SCHEMBL2641179 0.83 L3MBTL1 (0.57) L3MBTL1CREBBPKDREPHB4KCNH2
SCHEMBL4653938 0.82 L3MBTL1 (0.65) L3MBTL1CREBBPKDREPHB4KCNH2
SCHEMBL27617536 0.80 L3MBTL1 (0.62) L3MBTL1CREBBPKDREPHB4KCNH2
SCHEMBL5025532 0.80 KDR (0.45) L3MBTL1KDRKCNH2MEN1MAPT
SCHEMBL562604 0.79 L3MBTL1 (0.53) L3MBTL1KDM4EKMT2APDK2
SCHEMBL15850330 0.79 L3MBTL1 (0.53) L3MBTL1CREBBPKDREPHB4KCNH2
SCHEMBL15841900 0.79 L3MBTL1 (0.53) L3MBTL1CREBBPKDREPHB4KCNH2
SCHEMBL13757017 0.79 L3MBTL1 (0.61) L3MBTL1CREBBPKDREPHB4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1478653-B1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2014-07-02 EP disclosed
US-6995143-B2 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2006-02-07 US disclosed
EP-1478653-A1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY Basilea Pharmaceutica AG (CH) 2004-11-24 EP disclosed
US-20030212011-A1 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-11-13 US disclosed
WO-2003072588-A1 MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212011-A1 Macrolides with antibacterial activity MRPL21, RPS21, MRPS18A L3MBTL1 1132/4885CREBBP 4006/4885KDR 4746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.